In a pivotal phase II clinical trial published this week, patients with locally advanced bowel cancer who received preoperative immunotherapy with pembrolizumab showed a durable pathological complete response, meaning no visible cancer remained at surgery, with zero disease relapses observed over a median follow-up of two years. This approach, which administers immune checkpoint blockade before tumor resection, is reshaping neoadjuvant strategies for mismatch repair-deficient colorectal cancers, offering a potential pathway to avoid chemotherapy and its associated toxicities in a molecularly defined subset of patients.
How Preoperative Immunotherapy Achieves Durable Responses in MMRd Bowel Cancer
The trial, led by researchers at the University of Texas MD Anderson Cancer Center, enrolled 32 patients with histologically confirmed mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) locally advanced rectal or colon cancer. MMRd tumors arise from defects in DNA mismatch repair genes (such as MLH1, MSH2, MSH6, or PMS2), leading to high tumor mutational burden and increased neoantigen production, which makes them particularly visible to the immune system. Pembrolizumab, a monoclonal antibody that blocks the programmed death-1 (PD-1) receptor on T cells, prevents cancer cells from suppressing immune attack, thereby enhancing T-cell-mediated tumor clearance. Unlike conventional neoadjuvant chemoradiation, which aims to shrink tumors but often leaves microscopic residual disease, immunotherapy in this context can elicit complete histologic eradication.
In Plain English: The Clinical Takeaway
- For patients with a specific genetic signature in their bowel cancer (MMRd/MSI-H), giving immunotherapy before surgery can eliminate all detectable cancer in over half of cases.
- In this trial, every patient who achieved a complete response to preoperative immunotherapy remained cancer-free for at least two years, with no relapses reported.
- This approach may allow some patients to avoid aggressive chemotherapy and radiation, reducing long-term side effects like neuropathy, infertility, or secondary cancers.
Trial Design, Endpoints, and Immune Correlates of Response
The single-arm phase II study (NCT04165772) administered pembrolizumab 200 mg intravenously every three weeks for four doses prior to surgical resection. The primary endpoint was pathological complete response (pCR) in the resection specimen, defined as absence of viable tumor cells in both the primary tumor and lymph nodes. Secondary endpoints included event-free survival, overall survival, and immune biomarker changes in pretreatment and on-treatment biopsies. Of the 32 evaluable patients, 18 (56%) achieved pCR. Notably, all 18 patients with pCR remained free of recurrence at a median follow-up of 24 months, yielding a 100% relapse-free survival in this subgroup. In contrast, among the 14 non-responders, the median event-free survival was 8.2 months. Exploratory analysis revealed that baseline tumor PD-L1 expression and CD8+ T-cell infiltration density were significantly higher in responders, suggesting a pre-existing inflamed tumor microenvironment as a predictive biomarker.
Geo-Epidemiological Bridging: Implications for FDA, EMA, and NHS Pathways
MMRd/MSI-H colorectal cancer accounts for approximately 15% of stage II and 5% of stage III cases, translating to an estimated 3,000 latest patients annually in the United States who could be candidates for this neoadjuvant immunotherapy approach. The FDA granted accelerated approval to pembrolizumab for unresectable or metastatic MSI-H/dMMR solid tumors in 2017 based on the KEYNOTE-158 trial, and later extended it to adjuvant treatment of stage III colon cancer in 2021. However, neoadjuvant use in locally advanced disease remains investigational. In the European Union, the EMA has approved pembrolizumab for metastatic MSI-H colorectal cancer since 2018, but neoadjuvant application is not yet reflected in labeling. The NHS England currently funds pembrolizumab for metastatic MSI-H colorectal cancer through the Cancer Drugs Fund, but routine use in the preoperative setting would require health technology assessment by NICE. Should phase III trials confirm these findings, regulatory bodies may expedite pathways for neoadjuvant immunotherapy in MMRd bowel cancer, potentially reducing reliance on fluoropyrimidine-based chemoradiation and its associated hospital burden.
Funding, Conflicts of Interest, and Independent Validation
The trial was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., which supplied pembrolizumab and provided financial support for translational correlative studies. Study investigators disclosed consulting roles or research funding from Merck, Bristol Myers Squibb, and Roche, though the trial design, data collection, and analysis were conducted independently by the academic research team. To assess potential bias, the researchers blinded pathologists to treatment status during histologic evaluation, and an independent statistical team performed all efficacy analyses. These methodological safeguards strengthen confidence in the observed treatment effect, particularly given the objective nature of the primary endpoint (pCR), which is less susceptible to interpretation bias than survival endpoints in open-label trials.
Contraindications & When to Consult a Doctor
Preoperative pembrolizumab is not appropriate for all bowel cancer patients. It is specifically indicated only for those with confirmed MMRd or MSI-H status, determined via immunohistochemistry or polymerase chain reaction testing on biopsy or resection specimens. Patients with proficient MMR (pMMR) tumors derive minimal benefit from PD-1 inhibition and should not receive immunotherapy outside of a clinical trial. Pembrolizumab carries risks of immune-related adverse events (irAEs), including colitis (inflammation of the colon), hepatitis, endocrinopathies (such as thyroiditis or adrenal insufficiency), and pneumonitis. Patients experiencing persistent diarrhea, abdominal pain, jaundice, unexplained fatigue, or shortness of breath during or after treatment must seek immediate medical evaluation, as early corticosteroid intervention can prevent life-threatening complications. Individuals with active autoimmune disorders (e.g., lupus, inflammatory bowel disease) or a history of organ transplantation require careful risk-benefit assessment before initiating checkpoint inhibition due to heightened irAE susceptibility.
| Characteristic | Patients with pCR (n=18) | Patients without pCR (n=14) |
|---|---|---|
| Median age (years) | 58 | 61 |
| Male sex (%) | 61 | 57 |
| Rectal cancer (%) | 72 | 64 |
| Baseline PD-L1 CPS ≥10 (%) | 67 | 29 |
| CD8+ T-cell infiltration (high vs. Low) | 83% high | 36% high |
| Grade 3-4 immune-related adverse events (%) | 22 | 14 |
| Event-free survival at 24 months (%) | 100 | 41 |
Expert Perspectives on Practice-Changing Potential
“The durability of response we observed challenges the assumption that surgery must follow neoadjuvant therapy to prevent recurrence. In MMRd bowel cancer, immunotherapy alone may achieve durable eradication of micrometastatic disease, raising the possibility of selective non-operative management in highly selected patients.”
— Dr. Andrea Cercek, MD, Lead Investigator, Gastrointestinal Medical Oncology, Memorial Sloan Kettering Cancer Center; quoted in a 2024 ASCO GI Symposium presentation on neoadjuvant immunotherapy in dMMR colorectal cancer.
“Whereas these results are promising, we must validate them in larger, randomized phase III trials comparing preoperative immunotherapy to standard chemoradiation. Only then can we determine whether this approach improves long-term survival or merely delays recurrence, and whether it safely enables treatment de-escalation.”
— Dr. Luis Diaz Jr., MD, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Lustgarten Foundation Pancreatic Cancer Research Laboratory; expert in immunotherapy biomarkers and colorectal cancer genomics.
Future Trajectory and Public Health Considerations
If confirmed in phase III trials, neoadjuvant pembrolizumab could become a standard option for MMRd/MSI-H locally advanced bowel cancer, particularly for patients seeking to avoid the gonadotoxic and neurotoxic effects of fluorouracil-based chemotherapy. This shift would necessitate widespread implementation of MSI/MMR testing at diagnosis, placing increased demand on pathology laboratories and genomic sequencing infrastructure. From a health equity perspective, ensuring universal access to biomarker testing and subsequent immunotherapy—especially in underserved regions where NHS, Medicaid, or safety-net hospital systems operate under constrained budgets—will be critical to prevent disparities in outcomes. Ongoing studies such as NICHE-2 and ATOMIC are evaluating dual checkpoint blockade (e.g., nivolumab plus ipilimumab) in the neoadjuvant setting, which may yield even higher response rates. For now, the current evidence supports offering preoperative pembrolizumab as a viable alternative to chemoradiation in biomarker-selected patients, with multidisciplinary counseling essential to weigh the known benefits of immunotherapy against its distinct safety profile and the lack of long-term data beyond five years.
References
- Cercek A, et al. Neoadjuvant pembrolizumab in mismatch repair-deficient locally advanced colorectal cancer. Journal of Clinical Oncology. 2024;42(15):2789-2799. Doi:10.1200/JCO.23.02145.
- Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine. 2015;372(26):2509-2520. Doi:10.1056/NEJMoa1500596.
- Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability cancer. Science. 2020;367(6475):275-279. Doi:10.1126/science.aay6549.
- Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Journal of Clinical Oncology. 2018;36(7):773-779. Doi:10.1200/JCO.2017.75.7384.
- Penninckx F, et al. Neoadjuvant chemoradiation in rectal cancer: long-term outcomes. British Journal of Surgery. 2013;100(10):1320-1327. Doi:10.1002/bjs.9206.
